Answers are grounded in this paper and cite their sources.
Assembled polydimethylsiloxane microfluidic devices were modified with a sulfobetaine polymer through continuous "tip-to-tip" modification, significantly reducing blood clotting and extending device patency under blood flow. This technology can be designed to enable the development of devices that can continuously work in whole blood, especially in an extracorporeal or in vivo environment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: